Market LIVE
Published markets; coverage varies by country
Product profile · United States

PRECEDEX

 ·  Patent Litigation & Settlement History ↓

IngredientDEXMEDETOMIDINE HYDROCHLORIDE
Application typeNDA
Application021038
Product002
Dosage formINJECTABLE
RouteINJECTION
StrengthEQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)
Approval date2013-03-13
Marketing statusPrescription
Status event—
ApplicantHOSPIRA
Product source

Current GenericRadar decision

Year2018
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2018-08-21
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2018-08-21
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
100163962032-01-04DP ————
———
82421582032-01-04DP ————
———
83384702032-01-04DP ————
———
84555272032-01-04U U-421———
———
86481062032-01-04DP ————
———
93207122032-01-04DP ————
———
96160492032-01-04DP ————
———
82421582032-07-04— ————
—2032-07-04—
83384702032-07-04— ————
—2032-07-04—
84555272032-07-04— ————
—2032-07-04—
86481062032-07-04— ————
—2032-07-04—
93207122032-07-04— ————
—2032-07-04—
96160492032-07-04— ————
—2032-07-04—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208532 / 001FINAL_APPROVAL · FINAL_APPROVED2018-08-21—BAXTER HEALTHCARE CORPNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208129 / 002FINAL_APPROVAL · FINAL_APPROVED2018-11-29—FRESENIUS KABI USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212791 / 001FINAL_APPROVAL · FINAL_APPROVED2019-12-04—WILSHIRE PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
206407 / 001FINAL_APPROVAL · FINAL_APPROVED2020-01-30—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207551 / 001FINAL_APPROVAL · FINAL_APPROVED2020-05-20—AMNEAL PHARMACEUTICALS CO GMBHNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209307 / 001FINAL_APPROVAL · FINAL_APPROVED2020-06-03—GLAND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209065 / 003FINAL_APPROVAL · FINAL_APPROVED2020-06-12—JIANGSU HENGRUI PHARMACEUTICALS CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212571 / 001FINAL_APPROVAL · FINAL_APPROVED2020-08-27—MYLAN LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208266 / 001FINAL_APPROVAL · FINAL_APPROVED2020-09-15—PH HEALTH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212857 / 002FINAL_APPROVAL · FINAL_APPROVED2020-11-23—TAGI PHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210321 / 001FINAL_APPROVAL · FINAL_APPROVED2020-12-07—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216604 / 001FINAL_APPROVAL · FINAL_APPROVED2023-05-15—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217308 / 001FINAL_APPROVAL · FINAL_APPROVED2023-06-07—MILLA PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
220315 / 001FINAL_APPROVAL · FINAL_APPROVED2026-02-25—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 14 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208532 / 001BAXTER HEALTHCARE CORPFINAL_APPROVAL · FINAL_APPROVED2018-08-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208129 / 002FRESENIUS KABI USA LLCFINAL_APPROVAL · FINAL_APPROVED2018-11-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212791 / 001WILSHIRE PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2019-12-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
206407 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2020-01-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207551 / 001AMNEAL PHARMACEUTICALS CO GMBHFINAL_APPROVAL · FINAL_APPROVED2020-05-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209307 / 001GLAND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2020-06-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209065 / 003JIANGSU HENGRUI PHARMACEUTICALS CO LTDFINAL_APPROVAL · FINAL_APPROVED2020-06-12 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212571 / 001MYLAN LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2020-08-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208266 / 001PH HEALTH LTDFINAL_APPROVAL · FINAL_APPROVED2020-09-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212857 / 002TAGI PHARMA INCFINAL_APPROVAL · FINAL_APPROVED2020-11-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210321 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2020-12-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216604 / 001AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2023-05-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217308 / 001MILLA PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2023-06-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
220315 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2026-02-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2018-08-21TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.